HLB SCIENCE Inc. (XKON:343090)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,080.00
+30.00 (1.46%)
At close: Dec 5, 2025
6.83%
Market Cap 37.11B
Revenue (ttm) n/a
Net Income (ttm) -2.55B
Shares Out 17.84M
EPS (ttm) -566.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,591
Average Volume 13,344
Open 2,095.00
Previous Close 2,050.00
Day's Range 2,020.00 - 2,095.00
52-Week Range 978.00 - 2,520.00
Beta 0.19
RSI 65.81
Earnings Date n/a

About HLB SCIENCE

HLB SCIENCE Inc. develops biological drugs with MoA to infectious diseases. Its pipeline includes DD-S052P, a candidate that exterminates germs and eliminates endotoxins; DD-A279, a new treatment to cure Alzheimer's Diseases by controlling LPS and Gram-negative bacteria; and DD-A514, a diagnosis kit for Alzheimer's diseases. The company was formerly known as Dandi Bio Science Co.,Ltd. and changed its name to HLB SCIENCE Inc. in March 2023. The company was founded in 2016 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 343090
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.